Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
https://www.creative-peptides.com/product/romidepsin-item-10-101-186-33671.html
Creative peptides is specialized in the process development and the manufacturing of bioactive peptides. We offer custom peptide synthesis, process development, GMP manufacturing as well as catalog products.The products in our catalog peptides without a stated purity are unconditionally guaranteed to be a minimum of 95% by HPLC. Each product will be shipped with a HPLC,MS, and COA.Creative peptides offers custom peptide services using a unique portfolio of specific technologies. We have profound...
View more >>
Basic Information
Business Type: Manufacturer
Product/Service (We Buy): 51 - 100 People
Ownership Type: Individual (Sole proprietorship)
Registered Capital: US$501 Thousand - US$1 Million
Year Established: 2005
Number of Employees: 51 - 100 People
Trade & Market
Main Markets: North America,Southeast Asia,Mid East,South America,Africa,Eastern Asia,Eastern Europe,Oceania,Western Europe
QA/QC: 0
Number of R&D Staff: 0
Total Annual Sales Volume: US$10 Million - US$50 Million
United States
